ICDs In Arrhythmogenic Mitral Valve Prolapse

Arrhythmogenic mitral valve prolapse (AMVP) is a recognised substrate for ventricular arrhythmia and, in a small but important group, sudden cardiac death. Mitral valve prolapse is common and often benign, yet particular combinations of leaflet morphology, ventricular ectopy, myocardial fibrosis and a previous malignant rhythm can signal a substantially different risk profile.

The implantable cardioverter-defibrillator (ICD) has a clear role when a patient has survived ventricular fibrillation or sustained ventricular tachycardia without a reversible cause. Its role is less straightforward when the patient has frequent premature ventricular contractions (PVCs), syncope, bileaflet prolapse or mitral annular disjunction but no documented life-threatening arrhythmia. In that setting, the device decision requires careful clinical judgement rather than a single echocardiographic measurement.

For Australian clinicians, this question arises across very different services. A patient may begin assessment with a GP in regional New South Wales, receive cardiac magnetic resonance imaging in Sydney or Melbourne, and have device implantation and follow-up through a metropolitan electrophysiology centre. Public hospital pathways, private cardiology, travel distances and access to specialist interrogation all influence practical planning.

The evidence base is developing through observational cohorts, imaging studies and inherited arrhythmia research. The Journal of Arrhythmia provides an open-access setting for following this work, including research on ventricular arrhythmias, catheter ablation, cardiac imaging and implantable devices.

Why Mitral Valve Prolapse Can Become Arrhythmogenic

Most people with mitral valve prolapse do not develop dangerous ventricular arrhythmias. The concern is a phenotype in which excessive leaflet motion and mechanical stress affect the mitral annulus, papillary muscles and adjacent inferobasal left ventricular myocardium. Repetitive traction may contribute to replacement fibrosis, creating areas capable of initiating or sustaining re-entry.

Clinical features associated with higher arrhythmic concern include bileaflet prolapse, mitral annular disjunction, marked leaflet redundancy, T-wave inversion in the inferior leads and frequent or complex PVCs arising from the papillary muscles or mitral annulus. Polymorphic ventricular ectopy, non-sustained ventricular tachycardia (NSVT), particularly when rapid or prolonged, and unexplained syncope add weight to the assessment.

The term AMVP should not be applied solely because a patient has mitral regurgitation and an abnormal ECG. Risk is better understood as an interaction between valve anatomy, electrical behaviour, ventricular function, fibrosis and clinical history. A patient with severe mitral regurgitation may need valve surgery for haemodynamic reasons, while a patient with modest regurgitation may still require investigation for an arrhythmic substrate.

Building A Patient-Specific Risk Assessment

Initial evaluation generally combines a detailed history, twelve-lead ECG, transthoracic echocardiography, ambulatory rhythm monitoring and assessment of left ventricular size and function. Monitoring should establish the PVC burden, morphology, couplets, NSVT rate and duration, as well as whether symptoms correlate with ventricular arrhythmia. A standard 24-hour recording may miss intermittent events, so longer monitoring is useful when palpitations or syncope are sporadic.

Cardiac magnetic resonance imaging can identify late gadolinium enhancement in the papillary muscles or inferolateral left ventricular wall, findings that may support the presence of an arrhythmogenic substrate. Imaging also helps distinguish scar from other causes of ventricular dysfunction and may clarify the effect of mitral regurgitation. Exercise testing can reveal exertional ventricular ectopy or changes in arrhythmia burden, although it should be selected according to the patient’s clinical condition.

Syncope deserves particular attention. A clearly vasovagal episode in a patient with a reassuring rhythm assessment is different from abrupt, unexplained syncope in someone with NSVT and mitral annular disjunction. Family history of sudden death, although not specific to AMVP, may alter the threshold for specialist review. Australian patients from remote communities may face delays in accessing cardiac MRI or electrophysiology review, making coordinated referral and interim safety planning especially important.

When An ICD Is Clearly Indicated

Secondary prevention is the strongest indication for an ICD. A patient with AMVP who has survived cardiac arrest caused by ventricular fibrillation, or who has sustained haemodynamically significant ventricular tachycardia without a reversible trigger, will generally be considered for defibrillator therapy if meaningful survival and acceptable functional status are expected.

The device can terminate ventricular fibrillation or fast ventricular tachycardia, but it does not remove the underlying trigger. Treatment of severe mitral regurgitation, optimisation of heart failure therapy, beta-blockade, antiarrhythmic medication and catheter ablation may all remain relevant. Papillary muscle or fascicular PVC ablation can reduce recurrent ventricular arrhythmia in selected patients, yet successful ablation does not automatically eliminate the need for an ICD after a major arrhythmic event.

Primary prevention is more nuanced. Reduced left ventricular ejection fraction may support ICD implantation under established heart failure criteria, particularly after appropriate medical therapy and an adequate period for recovery. In AMVP with preserved or mildly reduced function, however, there is no universally accepted risk score that reliably identifies every patient who will benefit. The decision should be made through an electrophysiology and structural heart team, with documented discussion of anticipated benefit and device-related harm.

Balancing Protection Against Device Burden

An ICD can be lifesaving, but implantation carries immediate and long-term consequences. Lead dislodgement, infection, pneumothorax, venous obstruction and inappropriate shocks are recognised complications. Over time, patients may face lead failure, generator replacement, pocket problems and restrictions related to driving or employment. These issues matter especially for younger people, who may live with the system for decades.

Inappropriate shocks can result from atrial fibrillation with rapid conduction, supraventricular tachycardia or oversensing. Programming with appropriate detection intervals, discrimination algorithms and specialist follow-up can reduce avoidable therapy. A subcutaneous ICD may be considered when bradycardia pacing, antitachycardia pacing and cardiac resynchronisation are not required, though it has its own limitations and does not provide conventional intracardiac pacing.

Shared decision-making should cover the possibility that an ICD may never deliver therapy. Patients often describe the prospect of a shock as frightening, while others value the reassurance of protection after a near-fatal event. Discussions should address driving rules, sport and work, travel, remote monitoring, end-of-life deactivation and the practical pathway for urgent review after a shock. In Australia, the choice between public and private care can affect waiting times, device clinic location and out-of-pocket costs, so these details should be made explicit rather than assumed.

Integrating Valve Treatment And Arrhythmia Care

Mitral valve surgery or transcatheter intervention may reduce regurgitant volume and ventricular stress, but its effect on sudden death risk in AMVP is not fully defined. Surgery should be guided by accepted indications for mitral repair or replacement, not used as a substitute for an ICD when a secondary prevention indication is present. Conversely, ICD implantation should not delay treatment of severe symptomatic regurgitation or progressive ventricular remodelling.

Ablation has a role when frequent PVCs are causing ventricular dysfunction, provoking ventricular tachycardia or producing substantial symptoms. Mapping can be technically demanding because papillary muscle ectopy may be multifocal or affected by catheter stability. Recurrence is possible, and continued surveillance remains necessary even after an apparently successful procedure.

Atrial arrhythmias can coexist with mitral valve disease and complicate device programming and anticoagulation decisions. Broader rhythm-care literature, including this related haemodialysis review, illustrates why comorbidity, medication safety and care coordination must be considered alongside the headline rhythm diagnosis. For an Australian patient moving between a local cardiologist, a tertiary service and hospital-based device clinic, clear records and a shared management plan are particularly valuable.

Follow-Up After The Implant Decision

Whether an ICD is implanted or deferred, AMVP requires longitudinal review. A reasonable programme may include periodic echocardiography, repeat ambulatory monitoring when symptoms change, ECG comparison and reassessment after mitral intervention. New syncope, a rising PVC burden, sustained palpitations or a change in ventricular function should prompt earlier evaluation rather than waiting for the next routine appointment.

Patients who do not initially meet ICD criteria should understand which findings would change the plan. Documented sustained ventricular tachycardia, cardiac arrest, significant myocardial scar, progressive ventricular dysfunction or recurrent unexplained syncope may lead to renewed discussion. An implantable loop recorder can sometimes help clarify the rhythm mechanism when symptoms are infrequent and the immediate ICD benefit remains uncertain.

Device patients need reliable interrogation and access to urgent advice after an alert or shock. This can be challenging for people in Far North Queensland, Western Australia or the Northern Territory, where travel to a pacing clinic may involve substantial time away from home. Telehealth and remote monitoring can support follow-up, although they do not replace in-person assessment when there is suspected infection, lead malfunction, repeated therapy or clinical deterioration.

The central principle is proportionality. AMVP should prompt active investigation when red flags are present, but the diagnosis alone is not an automatic indication for defibrillator implantation. The best decision combines the arrhythmic history, ECG, rhythm burden, imaging findings, ventricular function, competing illness, patient preferences and the quality of follow-up that can realistically be provided.

Clinicians, trainees and researchers can explore current evidence through the Journal of Arrhythmia and use the editorial office for publication or journal enquiries. Care teams should bring suspected high-risk AMVP cases to an experienced electrophysiology service, document the reasoning behind ICD decisions and maintain structured surveillance for patients whose risk may evolve.